Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1 Clinical Trial to Identify the Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors

Trial Profile

An Open-label, Phase 1 Clinical Trial to Identify the Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs Asciminib (Primary)
  • Indications Colon cancer; Gastric cancer; Gastrointestinal stromal tumours; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors ABL Bio
  • Most Recent Events

    • 03 Dec 2018 Results presented in a TRIGR Therapeutics media release.
    • 03 Dec 2018 According to a TRIGR Therapeutics media release, till date ABL Bio have enrolled 12 patients in this study.
    • 29 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top